Mediterr J Rheumatol 2019;30(2):86-9
Autoantibody Profiles in Autoimmune Rheumatic Diseases
Authors Information

Laboratorio di Patologia Clinica, Ospedale San Antonio, Tolmezzo, Azienda Sanitaria Universitaria Integrata di Udine, Italy

  1. Lopez-Longo FJ, Rodriguez-Mahou M, Escalona-Monge M, González CM, Monteagudo I, Carreño-Pérez L. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 2003;12:623-9. [https://doi.org/10.1191/0961203303lu439oa] [PMID: 12945722]
  2. Wu T, Mohan C. Proteomic toolbox for autoimmunity research. Autoimmun Rev 2009;8:595-8. [https://doi.org/10.1016/j.autrev.2009.01.019] [PMID: 19393208]
  3. Tozzoli R, Bonaguri C, Melegari A, Antico A, Bassetti D, Bizzaro N. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med 2013;51:129-38. [https://doi.org/10.1515/cclm-2012-0191] [PMID: 23092800]
  4. Tozzoli R, D’Aurizio F, Villalta D, Bizzaro N. Automation, consolidation, and integration in autoimmune diagnostics. Autoimmun Highlights 2015;6(1-2):1-6. [https://doi.org/10.1007/s13317-015-0067-5] [PMID: 26138781] [PMCID: PMC4536237]
  5. Bizzaro N, Tozzoli R, Villalta D. Autoimmune diagnostics: the technology, the strategy and the clinical governance. Immunol Res 2015;61:126-34. [https://doi.org/10.1007/s12026-014-8587-z] [PMID: 25398640]
  6. Bizzaro N. Can solid-phase assays replace immunofluorescence for ANA screening? Ann Rheum Dis 2018;Dec 8. [Epub ahead of print]. [https://doi.org/10.1136/annrheumdis-2018-214805] [PMID: 30530824]
  7. Bizzaro N, Brusca I, Previtali G, Alessio MG, Daves M, Platzgummer S, et al. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoimmun Rev 2018;17:541-7. [https://doi.org/10.1016/j.autrev.2017.12.007] [PMID: 29631063]
  8. Liaskos C,  Marou E,  Simopoulou T,  Gkoutzourelas A,  Barmakoudi M,  Efthymiou G, et al. Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece. Mediterr J Rheumatol 2018;29:120-6. [https://doi.org/10.31138/mjr.29.3.120]
  9. Bizzaro N. Autoantibodies as predictors of disease: The clinical and experimental evidence. Autoimm Rev 2007;6:325-33. [https://doi.org/10.1016/j.autrev.2007.01.006] [PMID: 17537376]
  10. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 2007;56:1736-44. [https://doi.org/10.1002/art.22708] [PMID: 17530702]
  11. Villalta D, Tozzoli R, Tonutti E, Bizzaro N. The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmun Rev 2007;6:359-65. [https://doi.org/10.1016/j.autrev.2007.01.009] [PMID: 17537381]
  12. Barturen G, Beretta L, Cervera R, van Vollenhoven R, Alarcón-Riquelme ME. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat Rev Rheumatol 2018;14:75-93. [https://doi.org/10.1038/nrrheum.2017.220] [PMID: 29362467]
  13. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018;75:1528-37. [https://doi.org/10.1001/jamaneurol.2018.2598] [PMID: 30208379]
  14. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63. [https://doi.org/10.1136/ard.2006.062901] [PMID: 17234652] [PMCID: PMC1954657]
  15. Zhu H, Luo H, Yan M, Zuo X, Li QZ. Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus. Genomics Proteomics Bioinformatics 2015;13:210-8. [https://doi.org/10.1016/j.gpb.2015.09.001] [PMID: 26415621] [PMCID: PMC4610965]
  16. Lewis MJ, McAndrew MB, Wheeler C, Workman N, Agashe P, Koopmann J, et al. Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. J Autoimmun 2018;91:1-12. [https://doi.org/10.1016/j.jaut.2018.02.009] [PMID: 29576246]
  17. Wiik AS, Bizzaro N. Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases. It is all about the patient! Auto Immun Highlights 2012;3:35-49. [https://doi.org/10.1007/s13317-012-0029-0] [PMID: 26000126] [PMCID: PMC4389069]
  18. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014;2014:315179. [https://doi.org/10.1155/2014/315179] [PMID: 24868563] [PMCID: PMC4020446]
  19. Fritzler MJ. Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev 2016;15:272-80. [https://doi.org/10.1016/j.autrev.2015.12.002] [PMID: 26687321]
  20. Satoh M, Tanaka S, Chan EKL. The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. Front Immunol 2015;6:181. [https://doi.org/10.3389/fimmu.2015.00181]
  21. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 2015;14:555-63. [https://doi.org/10.1016/j.autrev.2015.01.017] [PMID: 25661979]
  22. Tozzoli R, Villalta D, Bizzaro N. Challenges in the standardization of autoantibody testing: a comprehensive review. Clin Rev Allergy Immunol 2017;53:68-77. [https://doi.org/10.1007/s12016-016-8579-y] [PMID: 27498835]
  23. Tonutti E, Bizzaro N, Morozzi G, Radice A, Cinquanta L, Villalta D, et al. The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics. Auto Immun Highlights 2016;7:9. [https://doi.org/10.1007/s13317-016-0080-3] [PMID: 27423928] [PMCID: PMC4947463]
  24. Bagnasco M, Grassia L, Pesce GP. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 2007;6:347-53. [https://doi.org/10.1016/j.autrev.2007.01.011]